RHINOLOGY Journal
Overview
publication venue for
- EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. 62:287-298. 2024
- Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE. 62. 2024
- Mepolizumab in CRSwNP/ECRS and NP: the phase III randomised MERIT trial in Japan, China, and Russia. 62. 2024
- Two-year outcomes of radiofrequency device treatment of the nasal valve for nasal airway obstruction. 62. 2024
- EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023*. 61:194-202. 2023
- Evaluating treatment response to mepolizumab in patients with severe CRSwNP. 61:108-117. 2023
- Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. 59:301-+. 2021
- Pocket guide: biologics in upper and lower airways in adults 2025
- Remission in chronic rhinosinusitis with nasal polyps (CRSwNP) 2025
- The EUFOREA pocket guide for chronic rhinosinusitis 2023
- Comparison of nasal valve dysfunction treatment outcomes for temperature-controlled radiofrequency and functional rhinoplasty surgery: a systematic review and meta-analyses 2024
Identity
International Standard Serial Number (ISSN)
- 0300-0729